The TriHealth Hatton Research Institute's Oncology research team, and researchers at TriHealth’s Cancer Institute and Mary Jo Cropper Family Center for Breast Care conduct important clinical trials targeting improvements in the prevention and treatment of specific kinds of cancer. Composed of a team of research nurses and clinical research assistants, the TriHealth Hatton Research Institute's Oncology research team has many decades of experience in oncology research.
Clinical trials supported by our Oncology research team include cooperative group trials sponsored by the National Cancer Institute, studies through the Catholic Health Initiative, and Pharmaceutical Trials.
Selected trials:
What is a Clinical Trial?
A clinical trial (also called “clinical research,” “research study,” and “protocol”) is a research study that evaluates a new test, drug or treatment in people to make sure it is safe and effective. Carefully conducted clinical trials are vital to discovering new, better, safer treatments for people, and improve health and quality of life.
Clinical trials are important today for many reasons, including:
- Contributing to improved scientific knowledge about cancer: how to detect it, and how to treat it, and even how to prevent it
- Possibly benefiting individual patients by providing newer and better treatments, and possibly, a cure
More Information
For additional basic information about clinical trials:
Clinical Oncology Trials
Oncology: Breast
|
| A011106: ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant Treatment (ALTERNATE) in postmenopausal women: A Phase III Study. Learn more.
Principal Investigator and Contact information:
Amie Jackson, MD
513 853 1300
Study Coordinator and Contact information:
Pamela Daniel, RN
513 865 5228
pam_daniel@trihealth.com
|
| A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (CT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy. Learn more.
Principal Investigator and Contact information:
Ann Kuritzky, MD
513 853 1300
Study Coordinator and Contact information:
Pamela Daniel, RN
513 865 5228
pam_daniel@trihealth.com
|
| CADENCE: Carboplatin and Docetaxel in Neoadjuvant Treatment of ER Negative, HER2 Negative Breast Cancer. Learn more.
Investigator and Contact information:
Apurva Mehta, MD
513 863 1300
Study Coordinator and Contact information:
Pamela Daniel, RN
513 865 5228
pam_daniel@trihealth.com
|
| EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemo-therapy vs. Observation in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy. Learn more.
Principal Investigator and Contact information:
Apurva Mehta, MD
513 853 1300
Study Coordinator and Contact information:
Pamela Daniel, RN
513 865 5228
pam_daniel@trihealth.com
|
| FLEX: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles. Learn more.
Principal Investigator and Contact information:
Apurva Mehta, MD
513 853 1300
Study Coordinator and Contact information:
Pamela Daniel, RN
513 865 5228
pam_daniel@trihealth.com
|
| MK3475-522: A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC) Learn more.
Principal Investigator and Contact information:
Apurva Mehta, MD
513 863 1300
Study Coordinator and Contact information:
Pamela Daniel, RN
513 865 5228
pam_daniel@trihealth.com
|
| NRG BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed By Weekly Paclitaxel With Or Without Carboplatin For Node-Positive Or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer. Learn more.
Principal Investigator and Contact information:
Apurva Mehta, MD
513 853 1300
Study Coordinator and Contact information:
Pamela Daniel, RN
513 865 5228
pam_daniel@trihealth.com
|
| NRG CC004: Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer Learn more.
Principal Investigator and Contact information:
James Pavelka, MD
513 862 1888
Study Coordinator and Contact information:
Pam Daniel, RN
513 865 5228
pam_daniel@trihealth.com
|
| NSABP B51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy. Learn more .
Principal Investigator and Contact information:
Corey Hobbs, MD
513 853 1300
Study Coordinator and Contact information:
Pamela Daniel, RN
513 865 5228
pam_daniel@trihealth.com
|
| NSAPB B55: A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With gBRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy. Learn more.
Principal Investigator and Contact information:
Amie Jackson, MD
513 853 1300
Study Coordinator and Contact information:
Nancy Firsich, RN
513 865 5569
nancy_firsich@trihealth.com
|
| S1207: Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (e3). Learn more.
Principal Investigator and Contact information;
Amie Jackson, MD
513 853 1300
Study Coordinator and Contact information:
Pamela Daniel, RN
513 865 5228
pam_daniel@trihealth.com
|
Oncology: Gastrointestinal
|
| A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair. Learn more.
Principal Investigator and Contact information:
David Draper, MD
513-853-1300
Study Coordinator and Contact information:
Audrey Maschino, RN
513-865-5565
Audrey_Maschino@trihealth.com
|
Oncology: Gynecology
|
| GOG 0225: Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Learn more.
Principal Investigator and Contact information:
James Pavelka, MD
513 862 1888
Study Coordinator and Contact information:
Diann Fischesser, RN
513 862 1892
diann_fischesser@trihealth.com
|
| GOG 0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus. Learn more.
Principal Investigator and Contact information:
James Pavelka, MD
513 862 1888
Study Coordinator and Contact information:
Diann Fischesser, RN
513 862 1892
diann_fischesser@trihealth.com
|
| NRG GY005: A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS). Learn more .
Principal Investigator and Contact information:
James Pavelka, MD
513 862 1888
Study Coordinator and Contact information:
Diann Fischesser, RN
513 862 1892
diann_fischesser@trihealth.com
|
| NRG CC004: Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer Learn more .
Principal Investigator and Contact information:
James Pavelka, MD
513 862 1888
Study Coordinator and Contact information:
Diann Fischesser, RN
513 862 1892
diann_fischesser@trihealth.com
|
| LCCC 1326: Metformin with the Levonorgestrel-Releasing Intrauterine Device for the treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients. Learn more.
Principal Investigator and Contact information:
Kevin Schuler, MD
513 862 1888
Study Coordinator and Contact information:
Diann Fischesser, RN
513 862 1892
diann_fischesser@trihealth.com
|
Oncology: Hematology
|
| PIPER: A Prospective, Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components. Learn more.
Principal Investigator and Contact information:
Thomas Coyle, MD
513 853 1300
Study Coordinator and Contact information:
Audrey Maschino, RN
513 865 5565
audrey_maschino@trihealth.com
|
Oncology: Lung Cancer
|
| A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST): A screening trial for A081105 and E4512. Learn more.
Principal Investigator and Contact information:
Andrew Parchman, MD
513 853 1300
Study Coordinator and Contact information:
Audrey Maschino, RN
513 865 5565
audrey_maschino@trihealth.com
|
| A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo In Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC). An ALCHEMIST Treatment Trial. Learn more.
Principal Investigator and Contact information:
Andrew Parchman, MD
513 853 1300
Study Coordinator and Contact information:
Audrey Maschino, RN
513 865 5565
audrey_maschino@trihealth.com
|
| EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers. Learn more.
Principal Investigator and Contact information:
Andrew Parchman, MD
513 853 1300
Study Coordinator and Contact information:
Audrey Maschino, RN
513 865 5565
audrey_maschino@trihealth.com
|
| E4512: Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations. An ALCHEMIST Treatment Trial. Learn more.
Principal Investigator and Contact information:
Andrew Parchman, MD
513 853 1300
Study Coordinator and Contact information:
Audrey Maschino, RN
513 865 5565
audrey_maschino@trihealth.com
|
Oncology: Melanoma/Skin
|
| CO39722: A Phase III, Open-Label, Multicenter, Two Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma. Learn more.
Principal Investigator and Contact information:
James Maher, MD
513 853 1300
Study Coordinator and Contact information:
Audrey Maschino, RN
513 865 5565
audrey_maschino@trihealth.com
|
Oncology: Sarcoma
|
| A091401: Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients with Metastatic or Unresectable Sarcoma. Learn more.
Principal Investigator and Contact information:
James Maher, MD
513 853 1300
Study Coordinator and Contact information:
Audrey Maschino, RN
513 865 5565
audrey_maschino@trihealth.com
|